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ABSTRACT
Prion diseases are unique neurodegenerative illnes-
ses associated with the conversion of the cellular
prion protein (PrP
C) into the aggregated misfolded
scrapie isoform, named PrP
Sc. Recent studies on
the physiological role of PrP
C revealed that this
protein has probably multiple functions, notably in
cell–cell adhesion and signal transduction, and in as-
sisting nucleic acid folding. In fact, in vitro findings
indicated that the human PrP (huPrP) possesses
nucleic acid binding and annealing activities, simi-
larly to nucleic acid chaperone proteins that play
essential roles in cellular DNA and RNA metabolism.
Here, we show that a peptide, representing the
N-terminal domain of huPrP, facilitates nucleic
acid annealing by two parallel pathways nucleated
through the stem termini. We also show that PrP of
human or ovine origin facilitates DNA strand
exchange, ribozyme-directed cleavage of an RNA
template and RNA trans-splicing in a manner similar
to the nucleocapsid protein of HIV-1. In an attempt
to characterize inhibitors of PrP-chaperoning in vitro
we discovered that the thioaptamer 50-GACACAAGC
CGA-30 was extensively inhibiting the PrP chaperoning
activities. At the same time a recently characterized
methylated oligoribonucleotide inhibiting the chap-
eroning activity of the HIV-1 nucleocapsid protein
was poorly impairing the PrP chaperoning activities.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) such
as Creutzfeldt-Jakob disease (CJD), kuru and fatal
familial insomnia (FFI) in humans, scrapie in sheep and
bovine spongiform encephalopathy (BSE) in cattle are a
group of fatal neurodegenerative diseases (1–3). A major
molecular characteristic of TSEs is the accumulation of a
misfolded, aggregated, partially protease-resistant prion
protein (PrP), named PrPres, in the central nervous
system (CNS) (1–3). Accumulation of PrPres appears to
take place by recruitment and templated transconforma-
tion of the normal cellular prion protein (PrP
C) by PrPres
(4–7), and is thought to induce functional damages to the
CNS. In support of this, generation of spongiform enceph-
alopathy requires the presence of both PrPres and PrP
C
since mice devoid of PrP
C are resistant to challenge with
the infectious prion agent (8).
The PrP
C is highly conserved in mammals and abun-
dantly expressed in cells of the nervous and lymphoreticu-
lar systems but its physiological role has remained for a
long time a matter of speculation (2,9). In fact, PrP null
mice were found to develop and reproduce normally (10),
or manifested only subtle phenotypic effects [reviewed in
(11)], suggesting that PrP
C has no essential function(s)
that could not be compensated by proteins with over-
lapping activities. Nevertheless, several functions have
been proposed for PrP
C, including superoxide dismutase
activity (12,13), participation in copper metabolism (14),
signal transduction (15) and neuroprotection [(16,17), and
references therein]. Recent studies revealed that PrP
C has
a crucial role in cell–cell adhesion and in signal transduc-
tion mediated by Src-related kinases in the zebraﬁsh
animal model (18). In addition, there are clear indications
that PrP
C assists nucleic acid folding and interactions in a
manner similar to cellular and viral nucleic acid chaper-
ones in vitro (19–21), and might well restrict retrovirus
replication (22,23).
In fact, there are many different nucleic acid binding
proteins that recognize DNA and RNA with a broad
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tous nucleic acid binding proteins (NABP) there exists a
class named nucleic acid chaperones, which provide assist-
ance to the folding of DNA and RNA by preventing and
resolving misfolding, and by chaperoning DNA/RNA
interactions (24,25). Thus nucleic acid chaperones are con-
sidered to be essential co-factors for many basic biological
processes including nucleic acid maintenance, RNA
splicing, transport and translation (24,25) and PrP
C
would be one of these proteins (19–21).
In an attempt to better understand the relationship
between the PrP
C and nucleic acids and its possible role
in nucleic acid metabolism, we investigated the nucleic
acid chaperoning activities of the recombinant human
and ovine PrP in vitro. Using ﬂuorescence resonance
energy transfer (FRET), we report that a prion peptide
representing the N-terminal domain of huPrP is very
active in facilitating nucleic acid annealing. Furthermore,
by using established nucleic acid chaperoning assays,
notably DNA strand transfer (26), ribozyme cleavage of
an RNA substrate (27,28) and RNA trans-splicing (29,30),
we show that the human and ovine PrPs are potent nucleic
acid chaperones. Recently we have been able to charac-
terize a potent oligonucleotide (ODN) inhibitor of the
nucleic acid chaperoning activity of the HIV-1 nucleocap-
sid protein (NC) in vitro and its inhibitory effect on virus
replication in primary human cells (31). This prompted
us to search for ODNs capable of inhibiting the nucleic
acid chaperoning activity of PrP. We discovered that a pre-
viously identiﬁed 50-GACACAAGCCGA-30 thioaptamer
binding to Syrian hamster (SHa) and human PrP (32)
was a potent inhibitor of PrP-chaperoning activity
in vitro, while the non-modiﬁed ODN was not, and a
methylated ODN speciﬁc for HIV-1 NC was slightly
inhibitory.
MATERIALS AND METHODS
Recombinant proteins
Recombinant human PrP (huPrP from residues 23–231),
the N-terminal region [huPrP(23–145)] and the C-terminal
region [huPrP(122–231)] were expressed in Escherichia coli
and puriﬁed to homogeneity (19). The N-terminal region
23–110 of huPrP was synthesized by fmoc chemistry and
puriﬁed to homogeneity by HPLC (19). The ovine PrP
(ovPrP, residues 25–234) was produced in E. coli and
puriﬁed to homogeneity (33). HIV-1 nucleocapsid protein
NCp7 and NC(12–53) lacking the N- and C-terminal
regions were obtained as pure proteins as previously desc-
ribed (19,34). Proteins were dissolved at 1mg/ml in buffer
containing 30mM HEPES pH 6.5, 30mM NaCl and
0.1mM ZnCl2. HnRNP A1 and YB-1/p50 were provided
by Christiane Branlant (France) and Lev Ovchinnikov
(Russia), respectively.
Plasmid DNAs and RNAs
Plasmids pS14, pS20 and pR3, for the ribozyme asssays,
were provided by E. Bertrand (Montpellier) (28) and
plasmids H1 and H2 for the trans-splicing assays by
Rene ´ e Schroeder (Vienna, Austria). All plasmid DNAs
were ampliﬁed in E. coli Rec A- cells and puriﬁed by
afﬁnity chromatography (Qiagen, USA). H1 DNA
(549nt of exon 1 and 131nt of the 50 part of the intron)
was linearized with SalI and H2 DNA (147nt of the 30 half
of the intron and 23nt of exon 2) was linearized with
BamHI, then transcribed. Templates pS14, pS20 and
pR3 were digested by Pst I, treated by Klenow polymerase
to remove the 30 strand overhang, and then the substrate
RNA and the ribozyme were generated by in vitro tran-
scription with modiﬁcations: for substrate RNA UTP was
at 10mM and 50mCi
32P-UTP (Amersham, UK) was
added. For the ribozyme, UTP was at 100mM with
10mCi of
32P-UTP. For the trans-splicing assays, RNAs
H1 and H2 were prepared by in vitro transcription with T7
RNA polymerase according to the manufacturer’s instruc-
tions (Promega) and labelled by incorporation of
35S-UMP during transcription.
Following RNA synthesis, the DNA template was re-
moved by treatment with RNase-free DNase I (Promega)
for 20min at 37 C, followed by phenol extraction and
ethanol precipitation. All RNAs were puriﬁed by 8%
PAGE in 7M urea, 0.5  TBE. RNAs were recovered by
elution in 0.3M sodium acetate, 0.1% SDS, for 4h at
37 C and ethanol precipitated. RNAs were dissolved in
sterile H2O and their integrity was veriﬁed by PAGE–
urea.
TAR DNA
ODNs used for DNA annealing corresponded to the
HIV-1 TAR sequences, in the sense and antisense orien-
tations, respectively. ODNs were purchased from
Eurogentec (Belgium). TAR ODNs are 56nt in length.
TAR(+) (sense):
50-GGTCTCTCTTGTTAGACCAGGTCGAGCCCG
GGAGCTCTCTGGCTAGCAAGGAACCC-30;
TAR(–) (antisense):
50-GGGTTCCTTGCTAGCCAGAGAGCTCCCGGG
CTCGACCTGGTCTAACAAGAGAGACC-30;
ODNs used for DNA strand transfer assays corres-
ponded to the HIV-1 repeated R sequences, in the sense
and antisense orientations, already described in (35,36).
TAR(–) and R(+) ODN were
32P-labelled with 50mCi of
32P-ATP using T4 polynucleotide kinase. Labelled ODNs
were puriﬁed by 10% PAGE, 7M urea in 50mM Tris–
borate, 1mM EDTA, pH 8.3 (0.5  TBE) and recovered,
ethanol precipitated and dissolved in sterile H2O before
use.
Oligonucleotides
The 12-nt long thioaptamer (GA-12; 50-GACACAAGC
CGA-30), with ﬁve modiﬁcations 50 to the dA residues,
mODN-11 (50-GGUUUUUGUGU-30 with a 20O-methyl
modiﬁcation at each residue) and ODN-11 (50-GGTTTTT
GTGT-30, without modiﬁcations) were obtained in a
highly pure form from Eurogentec (Belgium). Ct-12 cor-
responds to GA-12 without the modiﬁcations.
Nucleic Acids Research, 2011,Vol.39, No. 19 8545Destabilization assay
To monitor the nucleic acid destabilizing properties of
huPrP, cTAR DNA was labelled either by carboxytetrame-
thylrhodamine (TMR) or ethyl 2-[3-(ethylamino)-6-ethyl-
imino-2,7-dimethylxanthen-9-yl]benzoate hydrochloride
(Rh6G) at its 50-end, while the 30 terminus was labelled
with either 4-(40-dimethylaminophenylazo) benzoic acid
(Dabcyl) or 5(and 6)-carboxyﬂuorescein (Fl). The dyes
form a non-ﬂuorescent heterodimer when the cTAR
stem is closed, while melting of the stem restores the
ﬂuorophore ﬂuorescence. Thus, the destabilizing ability
of HuPrP peptide (23–110) was evaluated from the ratio
of the ﬂuorescence intensity in the presence versus the
absence of the peptide. Experiments were performed by
adding huPrP (23–110) at increasing peptide to oligo-
nucleotide ratio to 50nM doubly labelled cTAR, in
25mM Tris, 30mM NaCl and 0.2mM MgCl2, pH 7.5.
Kinetics of cTAR-dTAR annealing with the huPrP
peptide (23–110)
The real-time annealing kinetics of cTAR with dTAR was
investigated by mixing Rh6G-50-cTAR-30-Dabcyl with an
excess of non-labelled dTAR in conditions already pub-
lished (35,37). Formation of the 55-bp cTAR/dTAR
extended duplex (ED) strongly increases the interchromo-
phore distance, leading to a full recovery of Rh6G
emission. The dependence of cTAR-dTAR annealing kin-
etics on temperature was performed at six different tem-
peratures, viz. 15, 20, 25, 30, 35 and 40 C, as previously
described (37).
The TAR(–)/TAR(+) annealing assay
Tar(+) and
32P-Tar(–) ODNs were incubated (0.03pmol
each) in 10ml of buffer A (35,37) in the presence of
increasing protein concentrations. Reactions were per-
formed at 37 C for 5min except for the positive control
which was incubated at 65 C. To stop the reaction and
denature the protein, we added 5ml of a solution contain-
ing 20% glycerol, 20mM EDTA, pH 8.0, 2% SDS, 0.25%
bromophenol blue and 0.4mg/ml calf-liver tRNA.
Samples were resolved by 8% native PAGE in 50mM
Tris–Borate, pH 8.3, 1mM EDTA at 4 C. Subsequently,
gels were autoradiographed and the amounts of labelled
single-stranded and double-stranded DNA were assessed
by PhosphorImaging.
Effect of inhibitors on the kinetics of cTAR-dTAR
annealing with the N-terminal huPrP
Inhibition of huPrP(23–110)-promoted cTAR-dTAR an-
nealing was performed by adding a 5-fold molar excess
of GA-12, mODN-11 or Ct-12 relative to cTAR/dTAR.
The cTAR (or dTAR)-huPrP(23–110)-ODN mixtures
were incubated for 5min to ensure that the binding equi-
librium was reached. Then, cTAR-dTAR hybridization
was initiated by manual mixing of cTAR-huPrP
(23–110)-ODN mixture with dTAR-huPrP(23–110)-
ODN mixture. To avoid the effects of local concentration
ﬂuctuations on the annealing kinetics, equal volumes of
the mixtures were used. Experiments were performed in
pseudo-ﬁrst order conditions by mixing 10nM of doubly
labelled cTAR with 300nM of non-labelled dTAR in
presence of huPrP(23–110) at a peptide/oligonucleotide
molar ratio of 1:1. To this mixture, inhibitors were
added in increasing concentrations (from 0.1- to
10-fold) to follow their concentration dependent inhibi-
tory effect.
All experiments were performed in 25mM Tris–HCl
(pH 7.5), 30mM NaCl, 0.2mM MgCl2 at 20 C.
DNA strand transfer assay
32P-labelled R(+) wt, non-labelled R(–) 30-modiﬁed and
R(–) wt were heat denaturated (2min at 90 C) and
chilled on ice. All components were kept on ice. An
amount of 0.03pmol each of R(+) wt and R(–)
30-modiﬁed were mixed with reaction buffer to a ﬁnal con-
centration of 20mM Tris–HCl, pH 7.0, 30mM NaCl,
0.1mM MgCl2,1 0 mM ZnCl2 and 5mM DTT in 5ml
ﬁnal volume, incubated for 30min at 65 C and chilled
on ice. Subsequently, 0.03pmol R(–) wt was added
together with the chaperone protein at a ﬁnal protein to
nucleotide molar ratio as indicated in ﬁgure legends.
Reactions were left to proceed for 1–5min at 37 C. The
mixtures were then chilled on ice and reactions stopped
with 2.5ml of 20% glycerol, 20mM EDTA pH 8.0, 0.2%
SDS, 0.25% bromophenol blue and 0.4mg/ml calf liver
tRNA. Samples were resolved by 6% native PAGE in
50mM TBE at 4 C. The level of strand exchange as a
function of time was quantiﬁed by PhosphorImaging.
Hammerhead Ribozyme cleavage assay
Ribozyme and substrate RNAs were independently heated
for 1min at 90 Ci nH 2O. The reaction buffer was added
to yield ﬁnal concentrations of 5mM MgCl2, 100mM
NaCl, 20mM Tris–HCl, pH 7.5. After slowly cooling
down to 37 C, RNAs were further incubated for 5min
at 20 C. An amount of 0.1pmol of ribozyme and
0.02–2pmol of RNA substrate were then combined in a
ﬁnal volume of 10ml, each protein was added at ﬁnal con-
centrations as indicated in the ﬁgure legend and incuba-
tions were for 1–30min at 37 C. Reactions were
terminated by adding 20ml of stop solution (0.3% SDS,
15mM EDTA), and RNAs were extracted with 30mlo f
phenol and 15ml of chloroform. The aqueous phase was
precipitated with ethanol and the pellet resuspended in
45% formamide, 0.5  TBE, and 0.1% dye. RNAs were
then analysed on 8% PAGE in TBE. All quantitative
measurements were done by PhosphorImaging.
Trans-splicing assay
An amount of 2 10
 8 M each of
35S-labelled RNAs were
incubated for 1min at 95 Ci nH 2O and cooled down to
37 C. Then, the splicing buffer (40mM Tris–Cl at pH 7.4,
3mM MgCl2, 0.4mM spermidine, 4mM DTT), 8U
RNasin (Promega) and
32P-GTP were added with the
nucleic acid chaperone, at protein to nucleotide molar
ratios as indicated in the ﬁgure legend, at 37 C for
30min in 10ml. Reactions were stopped by adding a
ﬁnal concentration of 40mM EDTA and 300mg/ml of
tRNA. Proteins were removed by phenol–chloroform
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Samples were resuspended in 10ml formamide buffer
(97% formamide, 1mM EDTA, 0.02% bromophenol
blue, 0.02% xylene cyanol), denatured for 2min at
95 C and resolved by denaturing 5% PAGE-7M Urea
in 0.5  TBE. Subsequently, the gel was ﬁxed, dried
and autoradiographed. 50 32P-labelled FX174 DNA
HinfI markers (Promega) were used for size determin-
ation (data not shown). Bands corresponding to the
product of the ﬁrst step of splicing (corresponding to the
G-I1 RNA, 132nt in length) were measured by
PhosphorImager.
RESULTS
In order to examine the nucleic acid chaperoning
(24,25,38) properties of the PrP, we have used advanced
assays [reviewed in (39)] that have been developed for the
characterization of key chaperone proteins implicated in
the metabolism of cellular RNAs such as hnRNP A1 and
FMRP proteins (28,40–42), and of retroviral RNA, like
the NC protein of retroviruses [(26,28,42), reviewed in
(43,44)]. Although the details of their mechanism of
action is incompletely understood, nucleic acid chaperones
are thought to facilitate RNA (and DNA) conforma-
tional rearrangements by a variety of ATP-independent
mechanisms, including destabilization of preformed
helices, charge neutralization and matchmaker activity
(24,25,45,46).
First, we have analysed the helix destabilizing activity
of the N-terminal peptide (23–110) of huPrP. Using the
doubly labelled cTAR DNA stem-loop (SL), there was no
evidence of helix destabilizing activity of huPrP(23–110) in
the present conditions, as observed by FRET (Figure 1A
and Supplementary Data). This differs from HIV-1 NC
protein, which shows signiﬁcant helix destabilizing activity
(47–49) (data not shown), but is similar to the behaviour
of the core protein of hepatitis C virus (HCV), another
well-characterized RNA chaperone with limited cTAR
melting activity (37). Next, we monitored the impact of
huPrP(23–110) on the annealing kinetics of cTAR/dTAR
by FRET.
Kinetics of cTAR-dTAR annealing facilitated by the
N-terminal peptide of huPrP
The real-time annealing kinetics of cTAR to dTAR was
investigated in pseudo-ﬁrst order conditions by mixing
Rh6G-50-cTAR-30-Dabcyl with an excess of non-labelled
dTAR (35,37). Formation of the 55-bp cTAR/dTAR
ED strongly increases the interchromophore distance,
leading to a full recovery of Rh6G emission. In the
absence of huPrP(23–110), the annealing of cTAR with
dTAR was very slow, involving two distinct kinetic com-
ponents with second-order rate constants. In the pres-
ence of huPrP(23–110) at a peptide/TAR ratio of 1/1,
the same ﬂuorescence plateau was observed as in the
absence of peptide, indicating that ED formation went
to completion. The huPrP(23–110) strongly accelerated the
annealing reaction, since it was completed in  30min,
instead of >1day without the peptide. An adequate ﬁt
of the annealing kinetic traces was obtained using a
bi-exponential function:
IðtÞ¼If  ðIf  I0Þ

ae ð kobs1 ðt t0ÞÞ  ð1   aÞeð kobs2 ðt t0ÞÞ

ð1Þ
where t0 is the dead time, kobs1,2 are the observed kinetic
rate constants, a is the amplitude of the fast component,
and I0 and If are the ﬂuorescence intensities of the SL and
the ED, respectively.
We already observed a fast and full ﬂuorescence
increase at the lowest tested oligonucleotide concentra-
tions (10nM cTAR and 100nM dTAR) (Figure 1), sug-
gesting that the peptide probably binds to the TAR
sequences with a high afﬁnity (>10
7M
 1). Indeed, if the
binding constant would be <10
6M
 1, and if we assume
that, as for other nucleic acid chaperones, PrP does not
exhibit any catalytic activity, most of the oligonucleotides
would be free and would anneal at the low speed observed
for cTAR and dTAR in the absence of protein.
Annealing as a function of the dTAR concentration
indicated a saturation behaviour of both kobs1 and kobs2
values as well as a constant value for their amplitudes
(Supplementary Figure S1B and Supplementary Data).
Moreover, the values of the intercept for both kobs1 and
kobs2 curves were very low, indicating that huPrP(23–110)
is unable to dissociate the ED. Based on these kinetic data,
a reaction mechanism with two parallel pathways can be
proposed (scheme 1), as for the HCV core-promoted
cTAR/dTAR annealing (37). Both the fast and slow
pathways are based on a distinct cTAR/huPrP(23–110)
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Figure 1. Promotion of cTAR/dTAR annealing by huPrP(23–110).
Kinetic trace of 10nM Rh6G-50-cTAR-30-Dabcyl with 100nM of
dTAR in 25mM Tris–HCl (pH 7.5), 30mM NaCl, 0.2mM MgCl2 at
20 C. huPrP(23–110) was added at a 1:1 molar ratio to cTAR and
dTAR. Excitation and emission wavelengths were 520nm and
550nm, respectively. The continuous grey line corresponds to the best
ﬁt of the data according to Equation (1), using kobs1=5.6 10
 3s
 1,
kobs2=6.8 10
 4s
 1 and a=0.7. Inset: Emission spectra of 10nM
doubly labelled cTAR (solid line), with 10nM huPrP(23–110) (dotted
line) and with 100nM dTAR+100nM huPrP(23–110) after completion
of the annealing reaction (dashed line).
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version step (kf1,2) coupled to a much faster, preceding
binding step, governed by an equilibrium constant
(KM1,2).
To further characterize the two pathways, the effect of
the sequence and stability of the oligonucleotides on the
huPrP(23–110)-promoted cTAR/dTAR annealing kinetics
was analysed. In this respect, dTAR was ﬁrst substituted
by the dTAR T-L mutant where the 6nt of the loop were
changed to T residues, thus preventing its base-pairing
with the cTAR loop. These nucleotide substitutions did
not signiﬁcantly change the time course of ED formation,
indicating that loop–loop interactions do not play a
signiﬁcant role (Supplementary Figure S1B and
Supplementary Data). Furthermore, to investigate the
role of the cTAR stem in the annealing reaction, we
used the cTAR1.2 derivative where bases complementary
to the bulged bases at Positions 49 and 52 have been
introduced in order to stabilize the lower half of the
stem. The annealing of this mutant to dTAR in the
presence of huPrP(23–110) was extremely slow
(Supplementary Figure S1C and Supplementary Data),
indicating that both kinetic pathways of the huPrP(23–
110)-promoted cTAR/dTAR annealing reaction are
nucleated through the stems of cTAR and dTAR.
The nature of the two pathways was further investigated
by analyzing the temperature dependence of the kobs
values (Supplementary Figure S1D and Supplementary
Data) using the Arrhenius equation:
ki ¼ Ai exp
Ea,i =RT

ð2Þ
where the rate constant ki is given by kobsi/[dTAR], Ai is
the pre-exponential Arrhenius factor, Ea,i is the activation
energy, R is the universal gas constant, and T is the tem-
perature (in Kelvin).
The temperature dependence of huPrP(23–110)-
promoted cTAR/dTAR annealing provided positive
enthalpy values for the transition state of 8.3 ( 0.7)
kcal/mol and 16.5 ( 1) kcal/mol for the fast and slow
pathways, respectively. These values indicated that
cTAR/dTAR annealing promoted by the huPrP(23–110)
peptide involves premelting of  2 and 4bp, for the fast
and slow pathways, respectively (50,51). Moreover, the
amplitude of the fast component was found to continu-
ously increase with temperature, as observed for the HCV
core (37).
Activation of DNA strand exchange by recombinant PrPs
The strand exchange assay (26) is designed to evaluate the
ability of the chaperone protein to facilitate formation of
the most stable nucleic acid conformation. It utilizes three
DNA molecules, namely the wild-type plus strand, (+) wt
(
32P-labelled), the wild-type minus strand, (–) wt, and the
mutated minus strand, (–) mut. DNA molecules (+) wt
and (–) wt are complementary, whereas (–) mut is only
partially complementary to (+) wt (see scheme in
Figure 2A). DNA molecules (+) wt and (–) mut are ﬁrst
heat annealed, giving rise to a double-stranded molecule
containing mismatches. Then, DNA (–) wt and either PrP,
or NCp7 as the positive control, were added to the pre-
formed double-stranded DNA [(+) wt:(–) mut] molecules
and incubated for 5min at 37 C (see ‘Materials and
Methods’ section). Last, nucleic acids were deproteinized
and analysed by PAGE under native conditions. The
strand exchange activity of the chaperone protein facili-
tates formation of the perfect double-stranded DNA [(+)
wt:(–) wt] molecules at the expense of [(+) wt:(–) mut]
molecules with mismatches (Figure 2A). If the recombin-
ant PrPs have general nucleic acid chaperoning activities,
they should facilitate formation of the most stable duplex
and thus activate the substitution of DNA (–) wt for (–)
mut in the double-stranded nucleic acid molecule
(Figure 2A).
The
32P-labelled DNA (+) wt is shown in lane 1 while
control double-stranded DNA [(+) wt:(–) wt] and [(+)
wt:(–) mut] are shown in lanes 3 and 4, respectively
(Figure 2B). Addition of DNA (–) wt to double stranded
[(+) wt:(–) mut] and incubation for 30min at 0 C (lane 5)
or 37 C (lane 6) did not result in any strand exchange.
Addition of HIV-1 NCp7 together with DNA (–) wt
resulted in a nearly complete strand exchange under the
conditions where NCp7 to nucleotide molar ratios were
1/12nt and 1/6nt (lanes 7 and 8, respectively). Mutant
NC(12–53) lacking the N- and C-terminal amino acids
has only limited strand exchange activity (lanes 9 and
10). HuPrP was found to strongly activate the strand
exchange (lanes 11 and 12). A polypeptide representing
the N-terminal disordered region of huPrP, huPrP(23–
145) (52), also exhibited a strong strand exchange
activity (lanes 13 and 14), whereas the polypeptide
huPrP(122–231), representing the C-terminal, well-folded
region of huPrP (52,53), had little activity (lanes 15 and
16). The recombinant ovine PrP (ovPrP) behaved in a
manner similar to huPrP, showing a strong strand
exchange activity (lanes 17 and 18) at protein tonucleotide
ratios of 1:12 and 1:6.
For kinetic analysis, DNA strand exchange assays were
performed at 30 C from one to several minutes with NC,
huPrP and ovPrP proteins at a protein to nucleotide molar
ratio of 1/12nt (see ‘Materials and Methods’ section). For
the wild-type NCp7, the exchange rate at 30 C was
0.031mol of DNA exchanged per mole of protein per
minute. For the mutant NC(12–53), this value was
reduced about nine times, but still was about three times
higher than that observed in the absence of NC protein.
The exchange rates for the recombinant PrPs were very
close to that for NCp7 (0.025, 0.03 and 0.03mol of DNA
KM1
KM2
IC1
IC2
ED
kf1
cTAR2 + dTAR kf2
cTAR1 + dTAR
Scheme 1. IC1 and IC2 represent intermediate complexes formed
during the fast and slow pathway, respectively. The values of the
KM1,2 and kf1,2 parameters (Table 1) determined from the ﬁts of
Supplementary Figure S1B were found to be close to the corresponding
values reported for the HCV core protein in the same system, strength-
ening the similarity between the mechanisms of huPrP(23–110)- and
HCV core-promoted cTAR/dTAR annealing reaction.
8548 Nucleic Acids Research, 2011,Vol.39, No. 19per mole of protein per minute at 30 C for huPrP,
huPrP(23–145) and ovPrP, respectively. For huPrP(122–
231), the value was  10 times lower than that for
huPrP(23–145).
Strand exchange assays have also been carried out with
cellular hnRNP A1 and p50, two well-characterized RNA
chaperone proteins (40–42). Both proteins proved to fa-
cilitate the strand exchange reaction, although at a rate
about three times lower than that observed under the
present experimental conditions for huPrP (data not
shown).
Facilitation of ribozyme-directed cleavage of an RNA
substrate by PrPs
Next, we used the hammerhead ribozyme-directed
cleavage of an RNA substrate to examine both the
RNA annealing and unwinding activities of nucleic acid
chaperones (27,28). Nucleic acid chaperones are thought
to enhance the rate of ribozyme cleavage by activating the
annealing of the substrate RNA to the ribozyme
(Figure 3A, step 1) and the unwinding and release of the
cleaved RNA products (Figure 3A, step 3), thus allowing
recycling of the ribozyme. The ribozyme cleavage assay
aims at examining whether PrP accelerates ribozyme
cleavage of an RNA substrate in a manner similar to the
viral NCp7 chaperone (Figure 3A) (27,28). We selected the
R3 hammerhead ribozyme and two RNA substrates,
namely S14, with a 14nt substrate–ribozyme duplex
length (7nt either side of the cleavage site) and S20, with
10nt either side of the cleavage site (28). The above RNA
substrate model system was chosen due its likely biological
relevance as evidenced by the similarity of data obtained
both in vitro and in cultured cells (28).
32P-labelled RNA
S14, the ribozyme and PrP were mixed and incubated for
30min. RNAs were deproteinized, recovered and analysed
by PAGE under denaturing conditions. In the absence of
B
A
Figure 2. Facilitation of DNA strand exchange by PrPs. (A) Assay schematic. DNA sequences representing the R region of HIV-1 are 96nt in
length. 50 32P-labelled R(+) wt was hybridized to R(–) mut to generate a double-stranded DNA with mismatches at the 30-end (step 1). Fully
complementary R(–) wt was added in the presence or absence of HIV-1 NCp7 or PrP (step 2). Strand exchange is visualized by native PAGE.
(B) Assays with 3 10
 9 M each of the DNA oligonucleotides were carried out at 37 Ci n1 0 ml (see ‘Materials and Methods’ section). Analysis of
the reaction products was by 6% PAGE under native conditions. *R=
32P-labelled DNA. Lanes 1 and 2: *R(+) wt alone and with R(–) mut at 0 C.
Lanes 3 and 4: *R(+) hybridized to R(–) wt and *R(+) hybridized to R(–) mut. Lanes 5 and 6: *R(+):R(–) mut incubated with R(–) wt at 4 and 37 C
for 30min. Lanes 7–18: 5min incubations with *R(+):R(–) mut and R(–) wt and with NCp7 (lanes 7 and 8), NC(12–53) (lanes 9 and 10), recom-
binant huPrP (lanes 11 and 12), huPrP(23–145) (lanes 13 and 14), huPrP(122–231) (lanes 15 and 16) or ovine PrP (lanes 17 and 18) at 6 10
 8 M
(protein to nucletide molar ratio of 1/12) (odd lanes) or 12 10
 8 M (protein to nucleotide molar ratio of 1/6) (even lanes). Proteins are indicated at
the top of the ﬁgure; double-stranded products [*R(+):R(–) wt] and [*R(+):R(–) mut] are indicated on the right. Arrow is direction of electrophoresis.
Note that the C-terminal region of huPrP is inactive (lanes 15 and 16).
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Figure 3. PrPs facilitate ribozyme cleavage of an RNA. (A) Assay schematic. A hammerhead ribozyme and a
32P-labelled RNA substrate were
generated by in vitro transcription and gel puriﬁed. Cleavage of the
32P-RNA by the ribozyme appears to ﬁrst necessitate hybridization of the
ribozyme to the substrate (step 1). After RNA cleavage (step 2), the products must be released to allow recycling of the ribozyme (step 3). At the end
of the reaction RNAs were deproteinized and analysed by PAGE under denaturing conditions to visualize the
32P-RNA products. In the absence of a
nucleic acid chaperone, hybridization of the RNA to the ribozyme and release of the products appear to be slow. Addition of a nucleic acid
chaperone will accelerate hybridization of the substrate to the ribozyme and dissociation of the products and thus ribozyme turnover. Base pairing
between the RNA substrate and ribozyme R3 are underlined on the substrate sequence. Ribozyme mediated cleavage occurs on the 30 side of A
(space). For RNA S14,...GAUUAAGUAGUA AGAGUGUCUGCA30, for RNA S20,...GAUUAAGUAGUA AGAGUGUCUGCA30.
(B) Ribozyme-directed cleavage of RNA substrate S14. A 1 10
 8 M of ribozyme R3 and 5 10
 9 M of RNA S14 were incubated as described
in the methods.
32P-RNA substrate (S14) and product ( S14) were analysed by denaturing 8% PAGE. Lanes 1 and 2: R3 and S14 at 4 or 37 C.
Lanes 3 and 5: HIV-1 NCp7 at NC concentrations of 2 10
 8,4 10
 8 and 8 10
 8 M (protein/nt molar ratios of 1/20, 1/10 and 1/5). Lanes 6–8:
NC(12–53) at concentrations of 1.6 10
 7, 3.2 10
 7 and 6.4 10
 7 M (molar ratios of 1/2.5, 1/1.2 and 1/0.6). Lanes 9–11: ovPrP at 2 10
 8,
4 10
 8 and 8 10
 8 M, respectively. Lanes 12–14: huPrP at concentrations of 2 10
 8,4  10
 8 and 8 10
 8 M, respectively. Lanes 15–17:
huPrP(23–110) at concentrations of 2 10
 8,4  10
 8 and 8 10
 8 M, respectively. Lanes 18–20: huPrP(23–145) at concentrations of 2 10
 8,
4 10
 8 and 8 10
 8 M, respectively. Lanes 21–23: huPrP(122–231) at concentrations of 2 10
 8,4  10
 8 and 8 10
 8 M, respectively. R3, S14
and the 50 sequences of S14 ( S14) are identiﬁed on the right. Markers are on the left. Arrow shows direction of electrophoresis. Note that the RNA
products rapidly accumulate in the presence of a chaperone whereas they do not in the absence of a chaperone. (C) Ribozyme cleavage of RNA S20.
Conditions were as in Figure 3B except that the substrate was S20 and protein concentrations of 4 10
 8 (odd lanes) and 8 10
 8 M (even lanes)
were used. Proteins are identiﬁed at the top of the ﬁgure. R3, S20 and the 50 sequences of S20 ( S20) are identiﬁed on the right. Markers are on the
left. Arrow shows direction of electrophoresis. Note that ribozyme-directed cleavage of S14 or S20 did not occur at 4 C (lane 1). Note that enhanced
ribozyme cleavage by PrPs is probably via their match-maker activity for the annealing of S14 RNA to the hammerhead ribozyme (step 1) and their
destabilizing activity upon S14 RNA cleavage (Step 3) [see ref. (25)].
8550 Nucleic Acids Research, 2011,Vol.39, No. 19a chaperone, ribozyme-directed cleavage of the RNA sub-
strate occurred only slowly at 37 C (Figure 3B, lanes 1 at
4 C and 2 at 37 C;
32P-RNA substrate is S14 and cleaved
product  S14). In agreement with previous reports (28),
HIV-1 NCp7 facilitated ribozyme cleavage of RNA S14 to
reach completion at a concentration as low as 2 10
 8 M
(lanes 3–5). On the other hand, NC(12–53) was relatively
inactive even at a concentration above 1 10
 7 M (lanes
6–8). Interestingly, PrP of ovine or human origin showed
strong enhancement of ribozyme cleavage at 2–4 10
 8 M
(lanes 9–11 and 12–14, respectively). The N-terminal
region of huPrP was very active (lanes 15–17 and 18–20)
while the C-terminal region was very poorly active (lanes
21–23).
We also examined the effect of PrP using the RNA sub-
strate S20, capable of forming an ED of 20nt with the
hammerhead ribozyme (Figure 3A) which precludes acti-
vation of ribozyme cleavage by HIV-1 NCp7 or hnRNP
A1 (28). In the absence of NCp7 or PrP, only minimal
ribozyme-directed cleavage of RNA S20 was observed at
37 C (Figure 3C, lane 2;
32P-RNA substrate is S20 and
product  S20) as seen with RNA S14 (Figure 3B, lane 2).
The enhancement of ribozyme cleavage of RNA S20 by
NCp7 remained very modest even at NCp7 concentration
of 4 10
 8 M (Figure 2C, lanes 3–4), in agreement with
reported data (28). Mutant NC (12–53) was also very
poorly active (lanes 5–6). The ovPrP and huPrP also
exhibited very little, if any, activity using RNA S20
[lanes 7–8, 9–10, 11–12 and 13–14, for ovPrP, huPrP,
huPrP(23–145) and huPrP(122–231), respectively].
Kinetic assays of ribozyme cleavage of RNA S14 were
performed with NCp7, huPrP and ovPrP at a concentra-
tion of 4 10
 8 M and cleavage monitored for up to
30min. Initial rates were 10–12mmol of RNA S14
cleaved at 37 C/min/mol of NCp7 and ovPrP. For
huPrP, the observed rate was 3-fold slower, while it was
approximately 100-fold slower for NC(12–53) at concen-
trations above 1 10
 7 M, although two to three times
above rates obtained in the absence of NC or PrP. Similar
results were obtained at huPrP or NC concentration of
1 10
 7 M (data not shown).
HuPrP and ovPrP facilitate RNA trans-splicing
To further examine the RNA chaperoning activity of the
mammalian PrPs, we used the previously established
trans-splicing assay (29,30) (Figure 4A), where the
pre-mRNA of the thymidylate synthase (td) gene contain-
ing a group I intron was split into two halves. The ﬁrst
RNA transcript, H1, corresponds to the 50 exon sequence
of 549 and 131nt of the intron while the second RNA
transcript, H2, represents the 30 part of the intron
(147nt) and part of exon 2 (23nt) (Figure 4A). The two
RNAs were
35S-UMP labelled during transcription and
were incubated together. Reaction was started by adding
32P-GTP, so that the resulting spliced RNA was
doubly labelled, internally and at the 50-end with
32P-GTP (Figure 4A). In the absence of protein, the
reaction was carried out at 55 C to allow a productive
interaction between H1 and H2 RNAs. Trans-splicing
was indeed found to take place at 55 C but only to a
limited extend [data not shown and (36)] but not at
37 C according to the accumulation of the
32P-GTP-I1
ﬁnal product (lane 1 in Figure 4B and C). As previously
reported (36) HIV-1 NCp7 strongly stimulated accu-
mulation of
32P-GTP-I1 and therefore trans-splicing
(lanes 2–5), with an optimal enhancement at a concentra-
tion of 8 10
 7 M (panel B, lane 4). Mutant NC(12–53)
was found to be poorly active even at 2 10
 6 M (panel B,
lane 7).
The recombinant huPrP was found to be a strong acti-
vator of trans-splicing (Figure 4B, lanes 8–11), with an
optimal activation at a concentration of 4 10
 7 M
(lanes 10 and 11). Interestingly the N-terminal huPrP
peptide (23–144) also activated trans-splicing (Figure 4B,
lanes 9–12) at concentrations of 2–4 10
 7 M (lanes 13
and 14) while the C-terminal domain (123–231) was
clearly inactive (lanes 16 and 17) under the present condi-
tions. The ovine PrP was already active at a concentration
of 2 10
 7 M (lanes 7–11 in panel C) and the N-terminal
huPrP peptide (23–110) was as active as the full length
huPrP (compare lanes 2–6 and 12–16 in panel C).
Inhibition of huPrP chaperoning activity by a thioaptamer
In a search for PrP-chaperoning inhibitors, we used a
12-nt long thioaptamer (GA-12; GACACAAGCCGA),
with ﬁve modiﬁcations 50 to the dA residues, since it was
found to bind with high afﬁnity to Syrian hamster, bovine
and human PrPs in vitro (32). We also selected a 11-nt 20
O-methyl oligoribonucleotide (mODN-11; GGUUUUUG
UGU) because it was shown to be a potent inhibitor of the
nucleic acid chaperoning activity of the HIV-1 nucleocap-
sid protein (31).
We examined the ability of these two selected oligo-
nucleotides, namely GA-12 and mODN-11, and of a
control ODN with the non-modiﬁed sequence GACACA
AGCCGA (Ct-12) to inhibit the annealing activity of
huPrP (Figure 5A and B). As shown in lanes 7–9, only
GA-12 at 100–200nM was able to completely inhibit
huPrP annealing activity, while mODN-11 (lanes 4–6)
and ODN Ct-12 (lanes 10–12) were poorly active. The
impact of such ODNs on the hammerhead ribozyme
directed cleavage of an RNA substrate was monitored
under the same conditions. Again the thioaptamer
GA-12 at 50–100nM was found to extensively inhibit
the RNA chaperoning of huPrP (lanes 7–9) while
mODN-11 at 100–200nM had moderate effect on huPrP
(lane 6) and ODN Ct-12 had no effect (lanes 10–12). Last,
we monitored the impact of these three ODNs on the
trans-splicing reaction facilitated by huPrP, and again
the thioaptamer GA-12 was efﬁciently (lanes 7–9) inhibit-
ing trans-splicing activation by huPrP, while Ct-12 and
mODN-11 were inactive (lanes 4–6 and 10–11). Results
obtained with ovPrP were very similar, namely an inhib-
ition of ovPrP chaperoning activity by GA-12 at 100nM
but not by mODN-11 and Ct-12 (data not shown).
We also examined the effect of GA-12 and mODN-11
on huPrP(23–110)-promoted cTAR/dTAR annealing
using FRET. Both GA-12 and mODN-11 decreased the
kinetics of huPrP(23–110)-promoted cTAR/dTAR an-
nealing but the decrease was more pronounced with
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Figure 4. Facilitation of RNA trans-splicing by PrPs. (A) Schematic representation of the trans-splicing assay: the two RNA constructs H1 of 680nt
in length (encoding exon 1 of 549nt and the 50 part of the intron of 131nt) and H2 of 170nt in length (encoding the 30 part of the intron of 147nt
and exon 2 of 23nt) have to fold into a splicing competent structure (step 1). The splicing reaction was started upon addition of the
32P-labelled
GTP. The recombinant PrP was added at step 2, where indicated. The ﬁnal RNA products are represented in step 4. All splicing rates were
monitored based on the levels of the ﬁnal product
32P-labelled GTP-I1 [see (B)]. (B and C) Assays where the H1 and H2 RNAs were incubated
with or without a nucleic acid chaperone, namely NCp7 or PrP. At the end of the reaction RNAs were phenol treated to remove the chaperone and
analysed by PAGE in denaturing conditions (see ‘Materials and Methods’ section). The RNA substrates (H1, H2), the ligated exons (E1-E2) and the
product (guanosine-50-intron G-I1) are indicated. Panel B. Lane 1: trans-splicing reaction at 37 C with RNA alone at a concentration of 4 10
 8 M.
Lanes 2–5: HIV-1 NCp7 at concentrations of 2.5, 5, 10 and 20 10
 7 M, corresponding to protein to nucleotide ratios of 1:128, 1:64, 1:32 and 1:16.
Lanes 6 and 7: NC(12–53) at concentrations of 1 and 2 10
 6 M, corresponding to peptide to nucleotide ratios of 1:32 and 1:16. Lanes 8–11:
recombinant huPrP(23–231) at concentrations of 2, 4, 8 and 16 10
 7 M, corresponding to PrP to nuceotide molar ratios of 1:160, 1:80, 1:40 and
1:20. Lanes 12–15: N-terminal huPrP(23–144) at the same protein to nucleotide ratios as for the huPrP(23–231). Lanes 16 and 17: C-terminal
huPrP(123–231) at protein to nt molar ratios of 1:40 and 1:20. Panel C. Lane 1: splicing reaction at 37 C with RNA alone at a concentration of
4 10
 8 M. Lanes 2–6: huPrP at concentrations of 1, 2, 4, 8 and 16 10
 7 M. Lanes 7–11: recombinant ovPrP at concentrations of 2, 4, 8, 16 and
32 10
 7 M. Lanes 12–16: huPrP(23–110) at concentrations of 1, 2, 4, 8 and 16 10
 7 M. Note that HIV-1 NCp7, huPrP and ovPrP strongly
activated trans-splicing at protein to nt molar ratios of 1:20 to 1:40. Peptides NC(12–53) and C-terminal huPrP(122–231) were very poorly active
(lanes 6, 7, 16, 17; in panel B).
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Figure 5. Thioaptamer inhibition of huPrP chaperoning activities in vitro. (A) Annealing of TAR(+)/TAR(–).The annealing conditions were exactly
as described in the ‘Materials and Methods’ section with the TAR(+) and TAR(–) DNA. PAGE analyses are described in ‘Materials and Methods’
section. Lane 1: Control at 65 C for 30min; lane 2: at 37 C for 30min. Lanes 3–12: with huPrP for 5min at 37 C. Lane 3: control showing the
complete hybridization of TAR(+) and TAR(–) DNA. Lanes 4–6: with mODN-11 added at the start of the incubation period at 50, 100 and 200nM.
No inhibition of huPrP annealing activity was observed. Lanes 7–9: with ODN GA-12 at 50, 100 and 200nM. Note that ODN GA-12 causes a
complete inhibition of huPrP chaperoning at 200nM. Lanes 10–12: with control ODN Ct-12 at 50, 100 and 200nM. (B) Ribozyme mediated cleavage
of an RNA substrate. The conditions for the ribozyme cleavage were exactly as described in the ‘Materials and Methods’ section with hammerhead
ribozyme and the RNA substrate. PAGE analyses under denaturing conditions are described in the ‘Materials and Methods’ section. Lane 1: Control
at 0 C for 30min; lane 2: at 37 C for 30min without PrP. Lanes 3: control with huPrP for 15min at 37 C showing a complete cleavage. Lanes 4–6:
with mODN-11 added at the start of the incubation period at 50, 100 and 200nM. Some inhibition of huPrP activity was observed at 100nM. Lanes
7–9: with ODN GA-12 at 50, 100 and 200nM. Note that ODN GA-12 causes a nearly complete inhibition of huPrP at 50nM and 100nM for ovPrP
(data not shown). Lanes 10–12: with control ODN Ct-12 at 50, 100 and 200nM. (C) The RNA trans-splicing reaction. The conditions for the trans-
splicing reactions were exactly as described in the ‘Materials and Methods’ section with the H1 and H2 RNAs. PAGE analyses under denaturing
conditions are described in the ‘Materials and Methods’ section. Lane 1: Control at 0 C for 30min; lane 2: at 37 C for 30min without PrP. Lanes 3:
control with huPrP at 8 10
 7 M for 30min at 37 C showing a complete cleavage. Lanes 4–6: with mODN-11 added at the start of the incubation
period at 50, 100 and 200nM. No inhibition of PrP activity was observed. Lanes 7–9: with ODN GA-12 at 50, 100 and 200nM. Note that ODN
GA-12 causes a nearly complete inhibition of huPrP at 100nM. Lanes 10–12: with control ODN Ct-12 at 50, 100 and 200nM.
Nucleic Acids Research, 2011,Vol.39, No. 19 8553GA-12 (Figure 6A). Finally, we analysed the concentra-
tion dependence of the inhibition of GA-12 on the
huPrP-promoted annealing of cTAR/dTAR (Figure 6A).
The inhibitory effect of GA-12 increased with its concen-
tration and appeared already when the GA-12 concentra-
tion was one order of magnitude lower as compared to
cTAR and dTAR concentrations. All kinetic traces in the
presence of GA-12 were adequately ﬁtted with Equation
(1) and showed a decrease in both kobs1 and kobs2 values
(Supplementary Table S1a and S1b). These data are con-
sistent with a tight binding of GA-12 to huPrP, which
reduces the concentration of huPrP available for
promoting the cTAR/dTAR annealing reaction. The in-
hibitor was also found to decrease the amplitude of the
fast pathway, further substantiating the hypothesis of a
huPrP sequestration by the inhibitor, since a similar
decrease in the amplitude of the fast pathway with the
concentration of protein was observed with the HCV
core protein (37).
Taken together these results show that the GACACAA
GCCGA thioaptamer is a potent inhibitor of the huPrP
nucleic acid chaperoning activity in vitro and this appears
to rely on the backbone modiﬁcations.
DISCUSSION
Collectively the data presented herein clearly show that
the human and ovine PrPs can assist the folding of
RNA and DNA molecules in physiological conditions
and at concentrations of 10
 7 M or below (Figures 1–5).
Thus, these two mammalian PrPs have the hallmarks of
bona ﬁde nucleic acid chaperones (24,25). In addition, the
chaperoning properties of the human PrP reside within
the N-terminal region of the protein (Figures 1–4).
Interestingly this N-terminal region possesses the charac-
teristic features of a chaperone (54,55) since it contains
aromatic residues and clusters of basic amino acids in an
intrinsically unstructured environment (52,56,57). Despite
the absence (or relaxation) of structural constraints on
mutations in the N-terminal domain of PrP, the
sequence and distribution of basic amino acids is highly
conserved between various mammalian PrPs (data not
shown).
As a consequence of its chaperone activity, the
N-terminal region of huPrP was found to activate by
two orders of magnitude the kinetics of the cTAR/
dTAR annealing reaction, probably through a reaction
mechanism similar to that described for the HCV core
protein (37). In this mechanism, the fast and slow
pathways were found to be nucleated through the cTAR
ends, but differ by the number of base pairs that should be
premelted in the original cTAR secondary structure to
nucleate the IC formation. In its free form, as a conse-
quence of the thermal fraying that occurs spontaneously
at room temperature, the closed cTAR species was shown
to be in equilibrium with partially melted cTAR species
where either the terminal or both the terminal and penul-
timate double-stranded segments of the stem are melted
(47–49). In this respect, the 8.3kcal/mol enthalpy energy
associated to the fast pathway is consistent with the
melting of the terminal double-stranded 3-bp segment,
which is poorly stable due to its position at the end of
the stem and the presence of the neighbouring G52
bulge. On the other hand, the 16.5kcal/mol enthalpy
energy associated with the slow pathway is consistent
with the energy needed to melt both the terminal and pen-
ultimate double-stranded segments of the cTAR stem
(Figure 7). As a consequence of this thermal fraying, the
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Figure 6. Inhibition of huPrP(23–110)-promoted cTAR/dTAR annealing. (A) Comparative effects of GA-12 and mODN-11. A 10nM of doubly
labelled cTAR was mixed with 300nM of non-labelled dTAR at a peptide/oligonucleotide molar ratio of 1:1 in the absence (blue) and presence of
GA-12 (black) and mODN-11 (red) sequences, added at ﬁve times molar excess, as compared to cTAR and dTAR. Excitation and emission
wavelengths were 520 and 550nm, respectively. The gray lines correspond to the ﬁts of the kinetic traces to Equation (1) and the ﬁtting parameters
given in Supplementary Table S1A. (B) Concentration dependence of the effect of GA-12 on the annealing kinetics. Kinetic traces were recorded with
10nM doubly labelled TMR-cTAR-Fl and 300nM non-labelled dTAR in the absence (black) and the presence of GA-12, added at 0.25  (green), 1 
(cyan), 5  (magenta) and 10  (yellow) molar ratio as compared to cTAR and dTAR concentrations. HuPrP(23–110) was added at a peptide/
oligonucleotide ratio of 1:1 Excitation and emission wavelengths were 480 and 520nm, respectively. All experiments were performed in 25mM Tris–
HCl (pH 7.5), 30mM NaCl, 0.2mM MgCl2 at 20 C. The gray lines correspond to the ﬁts of the kinetic traces to Equation (1) and the ﬁtting
parameters given in Supplementary Table S1B.
8554 Nucleic Acids Research, 2011,Vol.39, No. 19PrP-bound cTAR1 species in the fast pathway is thought
to form IC1, stabilized by the seven intermolecular base
pairs resulting from the annealing of both the 30 and 50
terminal strands of cTAR with the complementary
terminal strands of dTAR. Since the KM values of IC1
and IC2 are similar, we suggest that the PrP-bound
cTAR2 species in the slow pathway anneals only
through one of its frayed strands with the complementary
dTAR sequence to form IC2, also stabilized by 7bp.
Further conversion of both ICs into the ED most
probably relies on the conformational rearrangement
and melting of the stable upper part of both TAR
species (58–61). As for the core protein of the hepatitis
C virus (HCV) (37,62,63), the interconversion rate of
IC1 into ED was found to be much larger than for IC2
(Table 1), probably as a consequence of the more
Table 1. Comparison of the kinetic parameters of the huPrP(23–110)- and HCV core-promoted cTAR/dTAR annealing
a
KM1 (M
 1)(  10
 6) KM2 (M
 1)(  10
 6) kf1 (s
 1)(  10
2) kf2 (s
 1)(  10
2)
HuPrP 2.2 ( 0.8) 1.5 ( 1) 1.1 ( 0.1) 0.15 ( 0.03)
HCV Core
b 4(  2) 1.4 ( 0.7) 4.5 ( 0.9) 1.6 ( 0.2)
aThe equilibrium and kinetic constants for HuPrP-promoted cTAR/dTAR annealing reaction are calculated, as described in Supplementary
Figure S1B.
bData from (37) in the same buffer, with a core/oligonucleotide molar ratio of 1.4.
Figure 7. Proposed mechanism for PrP-promoted cTAR/dTAR annealing. The two pathways of the annealing reaction are thought to rely on the
thermal fraying of cTAR that leads to a fast equilibrium (microseconds range) between the premelted cTAR species (cTAR1 and cTAR2) (47). The
upper and lower pathways are associated with the fast and slow kinetic components, respectively. In both pathways, the cTAR species nucleate an
intermediate complex (IC) through the stem termini. Then, the ICs are converted in a rate-limiting step into the ﬁnal extended duplex (ED).
Nucleic Acids Research, 2011,Vol.39, No. 19 8555favorable zippering mechanism adopted by IC1 as
compared to the invasion mechanism adopted by IC2
(Figure 7).
With respect to NCp7, the natural partner of HIV-1
cTAR and dTAR sequences, data revealed that the equi-
librium constant KM for IC formation was two orders of
magnitude lower for the N-terminal region of huPrP than
for NCp7 added at a ratio of 10 peptides per oligonucleo-
tide (K=10
8M
 1) (64). This difference may in part be
explained by the incomplete coating of the oligonucleo-
tides by huPrP(23–110), since the KM value of the IC
was shown to be strongly dependent on the level of
protein coating in the case of NCp7 (with about three
orders of magnitude difference between low and full
coating). Interestingly, the interconversion rate value of
the fast pathway for the N-terminal region of huPrP was
close to the value (0.03s
 1) of the corresponding param-
eter obtained with NCp7. The comparison of this param-
eter for the two proteins is more straightforward, since this
parameter was found to be only poorly dependent on the
level of NCp7 coating (64). Thus, huPrP(23–110) appears
to promote the conversion of IC1 to the ﬁnal ED with the
same efﬁciency as NCp7. Moreover, as for NCp7
(35,64,65), huPrP(23–110) was found to nucleate the
cTAR/dTAR annealing reaction through the stems of
cTAR and dTAR but without destabilization of the
termini (Figure 1, inset). As for the HCV core protein,
this is a likely consequence of the stronger ‘nucleic acid
aggregating’ properties of the huPrP peptide that compen-
sate for the absence of its destabilizing activity. This pro-
pensity of the huPrP N-terminal peptide to efﬁciently
neutralize the negatively charged oligonucleotides and
promote their aggregation is probably related to the
more ﬂexible nature of this peptide, as compared to
NCp7 with the structured zinc ﬁngers (66,67).
It is hypothesized that such a disorder status of the
N-terminal domain of PrP allows for the recognition of
a rather large number of cellular and viral RNA se-
quences, as well as protein partners, as amply shown for
the cellular protein FMRP and the retroviral NC proteins
[reviewed in (54)]. Recognition of many partners by
nucleic acid chaperones favours the notion that these ubi-
quitous proteins can achieve several functions as
exempliﬁed by retroviral NC proteins in virus structure,
genome replication and virus assembly [reviewed in
(68,69)] and the cellular p53 and p50 proteins in DNA
maintenance and mRNA translation, respectively (40,70).
What is the function of PrP and what could be its role as
an RNA chaperone? For a long time the physiological
function of PrP
C remained a matter of speculation and
debate. Recent data demonstrated that PrP is involved
in cell–cell adhesion whereby it controls cell movements
in the early gastrula of zebraﬁsh embryos [reviewed in
(71)]. In addition, PrP appears to trigger cellular signalling
via Src-related kinases especially in neurons (18). These
cellular functions of PrP could well be linked to the fact
that PrP is, at least in part, a membrane associated protein
through its GPI anchor or its transmembrane domain
[reviewed in (72)]. Regarding the RNA chaperoning
activity, PrP could act at the level of mRNA translation
as shown for some fungal PrPs (73) and for the prion-like
neuronal protein CPEB (cytoplasmic polyadenylation
element binding protein) (74). In agreement with this
notion, we have recently found that a fraction of huPrP
is associated with translating ribosomes in human cells,
impacting on mRNA translation notably in cells in the
G2M phase (to be published elsewhere). Thus PrP
would be another chaperone protein associated with the
cellular translation machinery (Supplementary Figure S2),
thereby regulating the level of mRNA translation in a
manner similar to other essential RNA chaperones such
as hnRNP A1 in every cell type and FMRP in neurons (to
be published elsewhere). Indeed, formation of PrP
C aggre-
gates and ﬁbrils upon binding to small nucleic acid mol-
ecules would have a negative impact on translation and
thus on the cell physiology (75,76), and might also be
involved in the pathological conversion of PrP
C to the
infectious form, ultimately facilitating prion propagation
[(77,78), reviewed in (75,79)].
We also report that a small thioaptamer (GA-12) is
capable of inhibiting the PrP chaperoning activity
in vitro but not that of HIV-1 NC (data not shown) At
the same time a small methylated oligoribonucleotide
(mODN-11), previously found to be a potent inhibitor
of HIV-1 NC in vitro and of HIV-1 replication in cells
(31), had little inhibitory potential against PrP. Kinetic
data suggest that the small thioaptamer functions by
tightly binding to the N-terminal domain of huPrP. This
in turn may cause the formation of a complex where the
N-terminal disordered domain adopts a stable ordered
conformation. Such thioaptamer derivatives were found
to delay the onset of prion disease in the mouse model
(80), most probably by binding to PrP
C, in turn preventing
its recruitment into aggregates of PrP
Sc. These results and
those recently published on HIV-1 NC pave the way for
the future development of highly modiﬁed oligonucleo-
tides to treat diseases caused by RNA viruses as well as
by a non-conventional agent.
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